TVM Life Science Ventures VII has made the first investment in Montreal-based Kaneq Bioscience, a spin out company of Kaneq Pharma. Kaneq Bioscience was created for developing a protein tyrosine phosphatase1B (PTP-1B) inhibitor, designed ...
Tags: TVM Life Science, Pharma, Kaneq Pharma
GI Dynamics has a started a US pivotal trial of its non-surgical device, designed to treat patients with obesity and uncontrolled type 2 diabetes. Flexible, tube-shaped EndoBarrier device, which is implanted into the gut, forms a physical ...
Tags: GI Dynamics, EndoBarrier device, diabetes
One likely effect of the growing number of young people with type 2 diabetes is that more and more people in their 20s and 30s are developing serious eye problems not correctable with glasses. "We've all been aware that obesity and ...
Tags: diabetes, eye problems, eye health, eye diseases
Poxel has raised €13m ($17m) in a series B round financing to develop and confirm efficacy data of Imeglimin, a drug used to treat type 2 diabetes. Imeglimin is a new tetrahydrotriazine-containing class of oral anti- diabetics, the ...
Tags: Poxel, efficacy data of Imeglimin, drug, ype 2 diabetes
Research-focused healthcare company Roche has introduced a new point-of care system for the diagnosis and management of metabolic syndrome,which is associated with a higher risk for cardiovascular and type 2 diabetes diseases. Using blood ...
Tags: Roche, Care System, Management, Metabolic Syndrome
ProMining Therapeutics and Roche have collaborated for the discovery of small molecule therapeutics against type 2 diabetes mellitus. According to the deal, ProMining will use its CavitIIRx platform in the discovery programme and will ...
Tags: collaboration, small molecule therapeutics, medical technology
CeQur, a developer of wearable delivery devices, has started a clinical study of PaQ insulin delivery device. The PaQ study is conducted by Thomas Pieber, head of endocrinology and metabolism division at Austria University Hospital. The ...
Tags: CeQur, clinical study, PaQ insulin delivery device, PaQ study
Medcan Clinic, a private health care clinic in Canada, has entered into a collaboration agreement with Pathway Genomics. Under the agreement, Pathway Genomics will allow Medcan's patients to use its Personal Genome Test. Using only a ...
Tags: Medcan Clinic, Pathway Genomics, collaboration agreement
Janssen Research & Development has submitted a New Drug Application (NDA) to the US FDA seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. ...
Male manufacturing workers are the most likely of all Victorian workers to have a high risk of type 2 diabetes, a Monash University study of half a million WorkHealth checks has found. According to the health snapshot, more than one third ...
Tags: Victorian workers, diabetes, health, work risk
Diabetes UK has called for a front-of-pack traffic-light labeling system for food products, in an effort to help tackle the rising tide of Type 2 diabetes. The focus was also on the importance of including carbohydrate content on all ...
Tags: Diabetes UK, labeling system, food products
GI Dynamics has obtained conditional approval from the US Food and Drug Administration (FDA) to initiate a pivotal clinical trial of its non-surgical EndoBarrier device. Flexible, tube-shaped EndoBarrier liner, which forms a physical ...
Tags: GI Dynamics, conditional approval, FDA, pivotal clinical trial
Furiex Pharmaceuticals said Takeda Global Research & Development Center has resubmitted New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone ...
Tags: Furiex Pharmaceuticals, NDAs, alogliptin and pioglitazone
Janssen Research & Development has submitted a new drug application (NDA) to the FDA for canagliflozin to treat adult patients with type 2 diabetes. The filing is based on a global Phase III clinical development program, including nine ...
Tags: Janssen Research&Development, SGLT2, cardiovascular study
Takeda Pharmaceutical has received a complete response letter from the US Food and Drug Administration (FDA) regarding its new drug applications (NDAs) for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. ...
Tags: FDA, alogliptin, clinical trial program